Status:

UNKNOWN

Influence of Rivaroxaban for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic PAD

Lead Sponsor:

Poznan University of Medical Sciences

Collaborating Sponsors:

Poznan University of Physical Education

Conditions:

Peripheral Arterial Disease

Eligibility:

All Genders

50-70 years

Brief Summary

The aim of the conducted research is to evaluate the protective effect of rivaroxaban (trade name of the Xarelto medicinal product), administered together with acetylsalicylic acid (ASA), in compariso...

Detailed Description

EXISTING KNOWLEDGE AND MAIN ASSUMPTIONS OF THE PROJECT. Atherosclerosis is the most common cause of peripheral artery disease (PAD). The first symptom of PAD is intermittent claudication (IC), which ...

Eligibility Criteria

Inclusion

  • 1\. PAD, the Fontaine classification II

Exclusion

  • Severe heart failure with known ejection fraction \<30% or NYHA class III or IV symptoms
  • High risk of bleeding
  • Stroke with one month or any history of hemorrhaging or lacunar stroke
  • Estimated glomerular filtration rate \<15 ml/ml
  • Need for dual antiplatelet therapy, other non-aspirin antiplatelet therapy/, oral anticoagulant therapy/
  • The known non-cardiovascular disease that is associated with poor prognosis (i.n, metastatic cancer)
  • History of hypersensitivity or known contraindication for rivaroxaban, aspirin
  • Systemic treatment with strong inhibitors of CYP 3A4 as well as p-glycoprotein or strong inducers of CYP 3M
  • Any known hepatic disease associated with coagulopathy
  • Concurrent participation in another study with an investigational drug
  • Known contraindication to any study-related procedures\* Concerns: Absolute contraindications to an exercise test
  • Respiratory failure
  • BMI above or equal 40
  • Musculoskeletal dysfunction preventing walking (e.g. amputations)

Key Trial Info

Start Date :

March 10 2021

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2024

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT04305028

Start Date

March 10 2021

End Date

December 31 2024

Last Update

March 10 2021

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.